NanoStrike Research
WellAir disinfection solutions have been shown to safely and effectively reduce bacteria, viruses, VOCs, and particulate matter in dozens of independent laboratory tests.
In case studies and field evaluations, our products have been demonstrated to reduce infection in real-world settings.
Visit Plasma Air's HVAC Air Purification Bipolar Ionization Research.
NanoStrike Research
WellAir disinfection solutions have been shown to safely and effectively reduce bacteria, viruses, VOCs, and particulate matter in dozens of independent laboratory tests.
In case studies and field evaluations, our products have been demonstrated to reduce infection in real-world settings.
Visit Plasma Air's HVAC Air Purification Bipolar Ionization Research.
Summary of the dozens of independent laboratory tests carried out on WellAir's NanoStrike technology.
Viruses
Name Reduc. Model SARS-CoV-2 99.997% NV 1050 SARS-CoV-2 99.75% NV 400 Human parainfluenza type 3 (HPIV3), Measles surrogate 99.87% NV 1050 Influenza A 99.9% NV 1050 Phi X 174 98.8% NV 1050 MS2 Bacteriophage, SARS-CoV-2 surrogate 99.99% NV 1050 MS2 Bacteriophage, SARS-CoV-2 surrogate 99.9995% NV 400 MS2 Bacteriophage, SARS-CoV-2 surrogate 99.99% NV 900 MS2 Bacteriophage, Influenza A surrogate 99.99% NV 900 MS2 Bacteriophage, Norovirus surrogate 99.99% NV 900 MS2 Bacteriophage, SARS-CoV-2 surrogate 99.991% NV 200 Influenza H1N1 51.8% NV 200 
Bacteria
Name Reduc. Model Enterobacter cloacae 99.99% NV 1050 Salmonella enterica 99.99% NV 1050 Listeria innocua 99.99% NV 1050 Mycobacterium smegmatis, Tuberculosis surrogate 97% NV 1050 Staphylococcus epidermidis, MRSA surrogate 99.94% NV 1050 Micrococcus luteus 99.2% NV 1050 Bacillus globigii endospores, Anthrax surrogate 99.99% NV 1050 Clostridicum difficile spores 99.9% NV 1050 Staphylococcus epidermidis 99.9% NV 1050 Staphylococcus epidermidis, MRSA surrogate 99.99% NV 400 Micrococcus luteus 97.7% NV 400 Bacillus globigii endospores, Anthrax surrogate 99.9969% NV 400 MRSA 99.99% NV 900 Bacillus subtilis 86.63% NV 900 
Mold Spores
Name Reduc. Model Aspergillus niger 99.99% NV 1050 Aspergillus niger 99.10% NV 900 
VOCS
Name Reduc. Model Nitrogen Dioxide 99.49% NV 1050 Formaldehyde 99.68% NV 1050 Toluene 99% NV 1050 - Reduction of Enterobacter, Salmonella, and Listeria
The Defend 1050 was shown to reduce 99.99% of aerolized Enterobacter cloacae, Salmonella enterica and Listeria innocua in 15 minutes and exceeded a 6 net log reduction in 20 minutes.
SARS-CoV-2 ReductionThe Defend 1050 achieved a 4.53 log10 reduction of live SARS-CoV-2 virus, which equates to a 99.997% percentage reduction, in 30 minutes. The live SARS-CoV-2 virus was not detectable after 30 minutes.
SARS-CoV-2 ReductionThe Defend 400 achieved an average live SARS-CoV-2 virus reduction of 8.76 x 103 TCID50/mL, which equates to a 99.75% percentage reduction, after 45 minutes.
SARS-CoV-2 ReductionThe Defend 1050 was shown to reduce MS2 bacteriophage, a surrogate for SARS-CoV-2, by 99.99% in 15 minutes at Aerosol Research and Engineering Laboratories in Kansas.
SARS-CoV-2 ReductionThe Defend 400 was shown to reduce MS2 bacteriophage, a surrogate for SARS-CoV-2, by 99.9995% in 45 minutes at Aerosol Research and Engineering Laboratories in Kansas.
SARS-CoV-2 ReductionThe Protect 200 was shown to reduce MS2 bacteriophage, a surrogate for SARS-CoV-2, by 99.991% in 180 minutes at Aerosol Research and Engineering Laboratories in Kansas.
Air ExchangeNovaerus NV950 (Protect 900) cleaned 100% of the air in a room of 22.65m3 (800 ft3) in 21-24 minutes, dependent on fan speed at the Cork Institute of Technology in Cork, Ireland.
Airborne Allergen ReductionThe Protect 800/900 shown to reduce overall allergens by 41.16%, including house dust mites, feline dander, canine dander, and pollen at Indoor Biotechnologies Ltd. in Cardiff, UK.
Aspergillus niger Spore ReductionThe Defend 1050 was shown to reduce aerosolized Aspergillus niger spores at Aerosol Research and Engineering Laboratories in Kansas.
Bacillus Globigii Endospores ReductionThe Defend 1050 showed a 4-log (99.99%) reduction in Bacillus Globigii endospores within 15 minutes, which was maintained over the prolonged operation (24 hours).
Bioaerosols ReductionThe Protect 900 was shown to reduce aerolized biologicals: Staphylococcus epidermidis (99.87% reduction), MS2 bacteriophage (99.99% reduction), Aspergillus niger fungus (99.1% reduction), and Bacillus subtilis endospores (86.63% reduction) at Aerosol Research and Engineering Laboratories in Kansas.
Clostridium difficile Spore ReductionThe Defend 1050 was shown to reduce 99.6% of airborne C. difficile within the first 20 minutes of operation and >99.9% after 40 minutes at Airmid Health Group Ltd. in Ireland.
Formaldehyde ReductionThe Protect 800/900 was shown to reduce formaldehyde by 85% during a 14-hour testing experiment at Avomeen Analytical Services in Michigan.
Formaldehyde ReductionThe Defend 1050 had an average net LOG reduction of 2.52 LOG across four tests and formaldehyde levels reached 0.00 ppm in an average of 1.1 minutes at Aerosol Research and Engineering Laboratories in Kansas.
Influenza A ReductionThe Defend 1050 was shown to reduce 99.9% of airborne Influenza A within the first 10-20 minutes of operation at the Airmid Health Group Ltd. in Ireland.
Influenza H1N1 ReductionThe Protect 200 effective at removing 51.8% of the Influenza H1N1 virus from the air after 1 passage (or 44 seconds) through the device.
Measles Virus ReductionThe Defend 1050 was able to reduce the concentration of human parainfluenza type 3 (HPIV3) (renamed human respirovirus 3), a surrogate for Measles virus, by 99.87% after 25 minutes at the Airmid Healthgroup in Ireland.
Micrococcus luteus ReductionThe Defend 400 was shown to reduce 97.7% (1.64 log) of Micrococcus luteus bacteria in 60 minutes.
Micrococcus luteus ReductionThe Defend 1050 was shown to reduce 99.2% (2.08 log) of Micrococcus luteus bacteria in 60 minutes.
Mycobacterium tuberculosis InactivationThe Protect 200 rendered all airborne Mycobacterium tuberculosis non-viable at Qualilife Diagnostics in India.
Mycobacterium tuberculosis Bacteria ReductionThe Defend 1050 was shown to reduce the concentration of M. smegmatis (surrogate for M. tuberculosis) by 97% after 30 minutes of operation at Airmid Healthgroup in Ireland.
Nitrogen Dioxide ReductionThe Defend 1050 reduced the chamber concentration of Nitrogen Dioxide (NO2) to 0.0 ppm at 7.5 minutes in all three trials at Aerosol Research and Engineering Laboratories in Kansas.
Particle ReductionThe Defend 1050 removed 99% of PM2.5 within 6.26 minutes and 99% of PM1.0 within 6.33 minutes at the Camfil Laboratories – Tech Center in Sweden.
Phi X 174 Virus ReductionThe Defend 1050 was shown to reduce phi X 174 virus by 98.8% in 30 minutes at the Korea Testing Laboratory.
Staphylococcus aureus (MRSA) ReductionThe Protect 900 was shown to reduce 99.99% of methicillin-resistant Staphylococcus aureus (MRSA) within 4 hours at Microbac Laboratories, Inc. in North Carolina.
Staphylococcus epidermidis Bacteria ReductionThe Defend 1050 was shown to reduce Staphylococcus epidermidis bacteria by 99.9% in 60 minutes at the Korea Testing Laboratory.
Staphylococcus epidermidis Bacteria ReductionThe Defend 1050 achieved a microbial cell reduction of 99.94% of Staphylococcus epidermidis within 15 minutes of operation at the Novaerus Research and Development Labs in Ireland.
Staphylococcus epidermidis Bacteria ReductionThe Protect 800/900 shown to reduce 95% of Staphylococcus epidermidis aerosol contamination in 30 minutes at the University of Huddersfield in England.
VOC ReductionThe Defend 1050 achieved 90% VOC removal after 6 - 16 minutes, dependent on fan speed at the Camfil Laboratories – Tech Center in Sweden.
Particle ReductionThe Defend 400 reduced PM 1 by 99.99% in 26 minutes with an eCADR of 340.7 m3/h. PM 2.5 was reduced by 99.99% in 25.9 minutes with an eCADR of 341.0 m3/h.
Bacillus Globigii Endospores ReductionThe Defend 400 achieved a net LOG reduction of Bacillus Globigii endospores after 45 minutes of 4.55 which is equivalent to a net percent reduction of 99.9969%.
Staphylococcus epidermidis Bacteria ReductionThe Defend 400 achieved greater than a log-4 reduction (>99.99%) of Staphylococcus epidermidis after 45 minutes.
- Evaluation of WellAir’s FDA-Cleared Defend 400 in hospital operating room
Hospital evaluates WellAir’s Defend 400 air cleaning device in an operating room — results showed a substantial reduction in airborne bacterial bioburden over an 2-day period.
Evaluation of WellAir’s FDA-Cleared Defend 1050 in hospital staff breakroomNorthwell Health evaluates WellAir’s Novaerus Defend 1050 air cleaning device in a staff breakroom — results showed a substantial reduction in airborne bacterial bioburden over an 18-day period.
Evaluation of WellAir’s Defend 400 in urgent care outpatient facilityDuring the 5 consecutive days in a normal operating urgent outpatient facility, the Defend 400 significantly reduced total bacterial count by 52%, which included a 60% reduction in opportunistic pathogens and a 43% reduction in pathogenic bacteria.
Evaluation of WellAir’s Protect 800/900 and Defend 1050 in hospital ICUsWellAir’s solutions help to reduce the microbial load in the air and surfaces and thus hospital-acquired infections. This intervention study was conducted in two similar ICUs between May to November of 2020.
Evaluation of the Novaerus Technology in a Dialysis CentreNovaerus reduces VOCs by 93%, airborne bacteria by 87% and molds by 67% at the Fresenius Dialysis Centres in Portugal.
Evaluation of the Novaerus Technology in an Emergency HospitalNovaerus shown to reduce airborne Staphylococcus by 100%, airborne bacteria by 89% and airborne fungi by 87% Bucharest Emergency University Hospital in Romania.
Evaluation of the Novaerus Technology in a HospitalNovaerus reduces environmental surface MRSA by 97% and reduces environmental surface TVC and environmental air MRSA at the Royal Free Hospital in London.
Evaluation of the Novaerus Technology in Hospital WardsNovaerus reduces staff sickness, ward odors, infections and antibiotic use. Wards with Novaerus have had no outbreaks of MRSA, C. diff, influenza, or norovirus since installation at the Leopardstown Park Hospital in Ireland.
Evaluation of the Novaerus Technology in an Infectious Disease HospitalNovaerus shown to reduce airborne bacteria and fungi 96% at the “Dr V. Babes” Hospital of Infectious and Tropical Diseases in Romania.
Evaluation of the Novaerus Technology in Intensive CareNovaerus NanoStrike technology shown to significantly reduce number of microorganisms at the Brothers Hospitallers of Saint John of God Hospital in Poland.
Evaluation of the Novaerus Technology in a Nephrology ClinicNovaerus shown to reduce bacterial loads on high surfaces and window sills as well as reduce overall infection rates by 23% compared to increase of infection rates by 35% in control section at Rigshospitalet in Denmark.
Evaluation of the Novaerus Technology in an Ophthalmology Operating RoomNovaerus reduces bacterial colony count in both the rooms that were being used and those that were empty at Ain Shams University in Egypt.
Evaluation of the Novaerus Technology in a Pediatric DepartmentNovaerus devices effectively reduce the number of airborne pathogens by 61% in the admission room of the Pediatric Department and by 19% in the Clinic of Pulmonology/Tuberculosis and Pulmonary Diseases at Międzyrzecz Hospital in Poland.
Evaluation of the Novaerus Technology in a Pulmonology DepartmentNovaerus reduces CFU rates by 82% and fungi count by 93% after 2 months of operation at Uzsoki Hospital in Hungary.
Evaluation of the Novaerus Technology in a Specialized HospitalThe Protect 200 and Protect 900 devices significantly reduce number of microorganisms as well as eliminate unwanted odors at Specialized Hospital in Chorzów, Poland.
- Jarvis Estate Winery Case Study
Jarvis Estate Winery in Napa, California provides customers with the best of everything including world-class cabernets and WellAir Air disinfection technology. Read more about how Jarvis Estate Winery uses WellAir.
Broward Children's Case StudyThis 20-month study compares the total number of respiratory nosocomial infections before and after implementation of the Protect 900 units.
Canterbury Tower Case StudyThis 35-month study compares the total number of respiratory nosocomial infections and infection rates before and after each implementation of the Protect 900 technology at Canterbury Tower in Florida.
Edgehill Case StudyThis 24-month study compares the total number of respiratory nosocomial infections before and after implementation of the Protect technology at Edgehill Nursing and Rehabilitation Center (ENRC) in Pennsylvania.
Haus an der Traisen Case StudySince 2014, the Haus an der Traisen nursing home in St. Pölten, Austria have supplemented their existing hygiene protocols with Novaerus air purification units to help control infection and reduce odor.
Hialeah Case StudyThis 24-month study compares the total number of repeat infections, nosocomial C. difficile infections, and nosocomial respiratory infections before and after implementation of the Novaerus technology at Hialeah Nursing and Rehab Center (HNRC) in Florida.
Linde Healthcare Case StudyLinde Healthcare, a Vienna-based healthcare company, had no existing healthy air solution in place for its 16 person open floorplan office space. Curious about Novaerus’s innovative technology, they reached out to learn more.
Mamos Delne Case StudyAfter learning about the safety and efficacy of Novaerus' low-energy plasma technology from a local distributor, and that the products are made with medical-grade materials, Kindergarten Mamos Delne in Lithuania tried the technology in each of their three classrooms.
Manchester Manor Case StudyThis 24-month study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology at Manchester Manor Health Care Center (MMHCC) in Connecticut.
Masfiv Medical Centre Case StudyAs COVID-19 rapidly spread across the globe, healthcare facilities around the world had to adapt and prepare for a pandemic. For Masfiv, a newly built medical centre in Spain specializing in reproductive medicine and gynaecological health, this meant maintaining minimal essential reproductive care services while containing the spread of coronavirus. In line with public health guidelines, Masfiv established a range of COVID-19 protocols. One of these protocols; 24/7 air disinfection technology by Novaerus.
Meadow View Case StudyThis 24-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology at Meadow View Nursing Center (MVNC) in Pennsylvania.
Naamans Creek Case StudyThis 28-month study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology at Naamans Creek Country Manor (NCCM) in Pennsylvania.
Page Case StudyThis 29-month study compares the average monthly rate of nosocomial respiratory infections before and after implementation of the Novaerus technology at Page Rehabilitation and Healthcare Center (PRHC) in Florida.
Patki Hospital Case StudyPatki Hospital, an IVF centre specialized in obstetrics, infertility and gynaecology in India, were looking for a solution to reduce airborne VOC and infection load in their lab. After investigating various options, the hospital decided to deploy a Novaerus Defend 1050. The result; improved outcomes and air quality.
Sante International Case StudySante International has provided solutions to the Romanian healthcare industry since 1992 and has partnered with Novaerus since 2014. Over a 3-month period, they proved Novaerus technology is more efficient and safer with no maintenance and at a low cost.
University of Szeged Case StudyAs part of a trial to measure background pollution and pathogenic organisms, Novaerus units were placed in 4 locations in the University of Szeged’s Department of Geriatrics and Chronic Diseases of the Internal Medicine Clinic No. 1 in Hungary. The medical clinic was interested in improving overall air quality in the geriatric and chronic disease wards.
Vernon Manor Case StudyThis 24-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology at Vernon Manor Health Care Center (VMHCC) in Connecticut.
Village at Manor Park Case StudyThis 23-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology at Village at Manor Park (VMP) in Wisconsin.
Wassan Dental Speciality Center Case StudyTwo weeks after installation, staff at Wassan Dental Specialty Centre in Oman observed a noticeable reduction in odor. Staff were reassured to know that Novaerus was operating continuously in the background to eliminate VOC, infectious pathogens and allergens from the air.
